Schering-Plough PEG-Intron
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Peginterferon alfa-2b is approved Aug. 7 for combination use with Schering's Rebetol (ribavirin) capsules for treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alfa and are at least 18 years old. PEG-Intron was initially approved as monotherapy for hepatitis C Jan. 19. Rebetol received approval July 25 as a separately marketed product for use in combination with Schering's Intron A (interferon alfa-2b, recombinant); previously, the agent was only available as part of a package with Intron